Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Otsuka’s new formulations to offset Abilify Maintena dual patent expiry impact, says GlobalData

Otsuka Pharmaceutical is poised for a strategic transition as it approaches the loss of market exclusivity of Abilify Maintena (Aripiprazole) in Europe and the US in October 2024. This significant development signals a forthcoming shift in the drug’s sales trajectory, highlighting Otsuka’s readiness to embrace changes with new formulations for continued growth in mental health […]
Read more

AI may automate diagnosis of lupus nephritis, says GlobalData

Systemic lupus erythematosus (SLE) is a chronic autoimmune that can affect multiple major organ systems in the body. One of its most severe manifestations is renal (kidney) involvement, known as lupus nephritis (LN). Although LN can be detected via blood or urine tests, a kidney biopsy is considered the most precise diagnostic approach. However, there […]
Read more

FDA awarded record number of review designations to CRISPR drugs in 2023, reveals GlobalData

In late 2023, Vertex Pharmaceuticals and CRISPR Therapeutics made history by gaining the first FDA approval for a CRISPR-based drug, exagamglogene autotemcel (Casgevy) for the treatment of sickle cell disease with vaso-occlusive crisis. This historic achievement coincided with a record number of 14 review designations awarded by the FDA to CRISPR-based therapies in 2023, according […]
Read more

Merck seeks to develop novel T-cell engager therapies with TriTAC platform, says GlobalData

Merck has recently agreed to acquire cancer drug developer Harpoon Therapeutics for about $680 million. The deal includes promising compounds undergoing Phase II trials for malignancies and access to the Tri-specific T cell Activating Construct (TriTAC) platform, positioning the US-based pharmaceutical giant for significant advancements in therapeutic innovation. The focus lies on contesting the evolving […]
Read more

BrainStorm Cell Therapeutics signals continued hope for NurOwn by securing patents, says GlobalData

BrainStorm Cell Therapeutics is still navigating a three-year regulatory journey for the NurOwn therapy that was initiated in February 2021, marked by the FDA’s initial discouragement of filing a Biologics License Application (BLA). However, the recent acquisition of three new patents for NurOwn and NurOwn-Exosomes remains a safeguard for NurOwn’s cell therapy, fostering hope for […]
Read more

Mazdutide positive phase III results to help Innovent gain widespread adoption in China obesity market, says GlobalData

Innovent Biologics has recently made a significant breakthrough in obesity treatment with mazdutide, showcasing promising Phase III (GLORY-1) results. Poised to enter the Chinese market, mazdutide heralds a new era in obesity management, reflecting the China-based biotech company’s commitment to innovative healthcare solutions and addressing the growing need for effective obesity treatments in one of […]
Read more

Drug price controls and emphasis on preventive care top solutions to address healthcare inflation, says GlobalData

Inflation in healthcare refers to the persistent increase in the cost of medical goods and services over time. This phenomenon is driven by a combination of factors, including advancements in medical technology, rising labor costs, pharmaceutical innovations, and the complex interplay of supply and demand within the healthcare market. While there are several options for […]
Read more

Despite argenx Vyvdura approval, quest for definitive myasthenia gravis cure persists in Japan, says GlobalData

Japan has recently approved argenx’s  Vyvdura (efgartigimod alfa and hyaluronidase-qvfc) subcutaneous (SC) injection for the treatment of adult patients with generalized myasthenia gravis (gMG), who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs). While introducing a novel subcutaneous administration route, Vyvdura adds to Japan’s myasthenia gravis (MG) treatment options. However, differentiation […]
Read more

Antibody drug conjugates focus draws global pharma giants attention to China, says GlobalData

Antibody-drug conjugates (ADCs) represent a significant breakthrough in targeted cancer therapy. By blending the specificity of monoclonal antibodies with the potency of cytotoxic drugs, ADCs offer a targeted approach to cancer treatment, minimizing the damage to healthy cells. China has become a major force in the advancement of this innovative field. Consequently, global pharma giants […]
Read more

Early diagnosis crucial for improving Gaucher disease patient outcomes, says GlobalData

Gaucher disease, a rare genetic disorder with significant health implications, has been at the forefront of recent medical discussions due to concerns over delayed diagnoses and treatment initiation. Despite advances in diagnostic methods, many patients still face extended periods before receiving an accurate diagnosis, impacting their treatment and overall health outcomes. The medical community, including […]
Read more

XORTX eyes CKD space with lead product XRX-008, says GlobalData

XORTX Therapeutics, a Canada-based late-stage clinical pharmaceutical company, has recently submitted a new patent for the treatment of chronic kidney disease (CKD). XORTX’s patent submission was supported by the efficacy and safety clinical data from a completed Phase II XRX-008 (oxypurinol) trial. If successful, it could be of high clinical value to physicians looking to […]
Read more

ADHD field presents significant opportunity for drug developers in 7MM, says GlobalData

Stimulants, amphetamines, and methylphenidates are the first-line treatment for moderate to severe attention-deficit/hyperactivity disorder (ADHD) across the seven major markets (7MM*). Non-stimulants are mainly utilized as second-line therapies due to their lack of efficacy. However, stimulants are highly controlled substances, and prescriptions are often restricted to 30 days. This creates a demand for non-stimulants with […]
Read more

Obesity care needs greater revolution, says GlobalData

Novo Nordisk and Eli Lilly have been dominating the obesity scene in the past year with the approval of their glucagon-like peptide-1 receptor (GLP-1R) agonists Wegovy and Zepbound. Although medicines with other mechanisms of actions are available on the market, GLP-1R agonists seem to have a greater impact on weight loss and the patient’s life. […]
Read more
1 … 23 24 25 26 27 … 108